CN105779640A

CN105779640A - miRNA biomarker and detection kit used for renal cancer diagnosis

Info

Publication number: CN105779640A
Application number: CN201610345730.4A
Authority: CN
Inventors: 崔学俊
Original assignee: Individual
Current assignee: Individual
Priority date: 2016-05-21
Filing date: 2016-05-21
Publication date: 2016-07-20

Abstract

The invention discloses a miRNA biomarker and a detection kit which are used for renal cancer diagnosis. The microRNA biomarker is formed by the following microRNAs: hsa miR 10b 5p, hsa miR 384, hsa miR 206, hsa miR 424 5p and hsa miR 224 5p. According to the invention, serology expression analysis is carried out on five miRNAs obviously in differential expression of renal cancer and para-carcinoma tissues (differential expression quantity is more than 2 folds, and CT value in RT PCR is smaller than 30) hsa miR 10b 5p, hsa miR 384, hsa miR 424 5p, hsa miR 206 and hsa miR 224 5p, results show that the five miRNAs are stably expressed in serum, consistency between expression of serum miRNA and tissues is good, hsa miR 10b 5p, has miR 384 and has miR 206 are in down-regulated expression, and has miR 424 5p and has miR 224 5p are in up-regulated expression. The five miRNAs can serve as a biomarker used for the renal cancer diagnosis, and the sensitivity and specificity of combined diagnosis are obviously higher than those of single miRNA diagnosis.

Description

MiRNA biomarker and detection kit for Diagnosis of Renal Cell Carcinoma

Technical field

The present invention relates to biological detection, be particularly used for microRNA biomarker and the detection kit of people's Diagnosis of Renal Cell Carcinoma.

Background technology

Renal cell carcinoma (abbreviation renal carcinoma) accounts for 2%-3% in adult malignancies, is that the common urinary system of China second is pernicious Tumor, is only second to bladder cancer.Excision is the maximally effective Therapeutic Method of Limitable renal cell carcinoma, but a lot of patient the most still can answer Send out.Overwhelming majority renal carcinomas in early days without clinical symptoms, Local advancement or metastasis when diagnosing at the beginning of some patients, it is impossible to pass through hands Art radical excision, and this some patients prognosis is the best.So, the early diagnosis of renal carcinoma is become particularly necessary.

MicroRNA (miRNA) is the non-coding microRNA being about 18-25 nucleotide of latest find, is evolving Upper high conservative, quantity accounts for the 1% of genome, has generally believed that miRNA and human diseases have close contacting, It is found to be people and provides new approaches in gene level understanding cancer.MiRNA is transcribing or post-transcriptional level negative regulation protein The expression of encoding gene: be combined by or approximation complete complementary non-fully complementary with its target gene mRNA, cause mRNA to drop Solve or suppress it to translate.The gene of human genome about 30% is regulated and controled by miRNA, cell growth, breed, break up and The many-side such as apoptosis plays important biological regulation effect.Research has proven to the Abnormal regulation of miRNA and is formed with tumor and enter Open up in close relations.The target gene majority of MiRNA be participate in transcribing, signal transduction, the gene of the biological effect such as tumor generation. Along with the research that deepens continuously of miRNA Yu cancer, find that miRNA is not only the initial stage that take part in formation of cancer, Also relate to disease condition change, to the sensitivity of medicine, patient's prognosis etc. many-side.It is subsequently based on the cancer of miRNA Gene therapy is taken advantage of a situation and is climbed up stage, highlights the biggest researching value.

Up to now, the diagnosis for renal carcinoma of the reliable microRNA biomarker is not yet found.

Summary of the invention

It is an object of the invention to provide the microRNA biomarker for Diagnosis of Renal Cell Carcinoma and detection kit.

The above-mentioned purpose of the present invention is achieved by techniques below scheme:

For the microRNA biomarker of people's Diagnosis of Renal Cell Carcinoma, including: hsa-miR-10b-5p, hsa-miR-384, Hsa-miR-206, hsa-miR-424-5p and hsa-miR-224-5p；The nucleotide sequence of described hsa-miR-10b-5p is such as Shown in SEQ ID NO.1；The nucleotide sequence of described hsa-miR-384 is as shown in SEQ ID NO.2；Described hsa-miR-206 Nucleotide sequence as shown in SEQ ID NO.3；The nucleotide sequence of described hsa-miR-424-5p is as shown in SEQ ID NO.4； The nucleotide sequence of described hsa-miR-224-5p is as shown in SEQ ID NO.5.

Further, described microRNA biomarker is human serum microRNA biomarker.

Lineup's Diagnosis of Renal Cell Carcinoma microRNA primer, the combination of probe, including hsa-miR-10b-5p primer, probe, Hsa-miR-384 primer, probe, hsa-miR-206 primer, probe, hsa-miR-424-5p primer, probe, hsa-miR-224-5p Primer, probe；Described primer includes before reverse transcription primer, quantitative PCR primer after primer and quantitative PCR；hsa-miR-10b-5p Reverse transcription primer sequence as shown in SEQ ID NO.6, before quantitative PCR, primer sequence is as shown in SEQ ID NO.7, quantitatively After PCR, primer sequence is as shown in SEQ ID NO.16；The reverse transcription primer sequence of hsa-miR-384 as shown in SEQ ID NO.8, Before quantitative PCR, primer sequence is as shown in SEQ ID NO.9, and after quantitative PCR, primer sequence is as shown in SEQ ID NO.16； The reverse transcription primer sequence of hsa-miR-206 as shown in SEQ ID NO.10, primer sequence such as SEQ ID NO.11 before quantitative PCR Shown in, after quantitative PCR, primer sequence is as shown in SEQ ID NO.16；The reverse transcription primer sequence of hsa-miR-424-5p is such as Shown in SEQ ID NO.12, before quantitative PCR, primer sequence is as shown in SEQ ID NO.13, and after quantitative PCR, primer sequence is such as Shown in SEQ ID NO.16；The reverse transcription primer sequence of hsa-miR-224-5p is as shown in SEQ ID NO.14, before quantitative PCR Primer sequence is as shown in SEQ ID NO.15, and after quantitative PCR, primer sequence is as shown in SEQ ID NO.16；Each microRNA The nucleotide sequence of probe is as shown in SEQ ID NO.17.

The tumor diagnosis kit of a kind of people's renal carcinoma, including microRNA primer as above, the combination of probe.

Further, the tumor diagnosis kit of described people's renal carcinoma also include reverse transcriptase, buffer, dNTPs, MgCl2, DEPC water, Taq enzyme and standard substance and/or reference substance.

Advantages of the present invention:

By renal carcinoma tissue, substantially (differential expression amount is more than 2 fold, CT in RT-PCR to the present invention with cancer beside organism's differential expression Value is less than 30) 5 kinds of miRNA hsa-miR-10b-5p, hsa-miR-384, hsa-miR-424-5p, hsa-miR-206 and Hsa-miR-224-5p carries out serology expression analysis, and result shows that these 5 kinds of miRNA are stable in serum and expresses, serum miRNA Expression and tissue there is good concordance, hsa-miR-10b-5p, hsa-miR-384 and hsa-miR-206 down-regulated expression, Hsa-miR-424-5p and hsa-miR-224-5p up-regulated.These 5 kinds of miRNA can as the biomarker of Diagnosis of Renal Cell Carcinoma, And the sensitivity of Combining diagnosis is significantly higher than sensitivity and the specificity of single miRNA diagnosis with specificity.

Detailed description of the invention

Further illustrate the essentiality content of the present invention below in conjunction with embodiment, but do not limit scope with this.To the greatest extent The present invention is explained in detail by pipe with reference to preferred embodiment, it will be understood by those within the art that, can be to the present invention Technical scheme modify or equivalent, without deviating from the spirit and scope of technical solution of the present invention.Embodiment is not noted The experimental technique of bright actual conditions, generally according to normal condition, such as the condition described in textbook and experiment guide, or according to Condition proposed by manufacturer.

Embodiment 1: the screening of renal carcinoma tissue's diversity miRNA

1 object and method

1.1 Specimen origin

After obtaining patient's informed consent, collect the hospitals of traditional Chinese and western medicine of Jiangsu Province and demonstrate,prove through pathology in April ,-2014 in April, 2013 Actually patients with renal cell carcinoma Post operation specimen 8 is right, including the cancer of 3 centimetres of range above of distance cancerous tissue of cancerous tissue specimen and pairing Other tissue, all patients the most all do not receive chemotherapy and radiotherapy.

1.2 key instrument equipment

Desk centrifuge: EppendorfMini spin (U.S.) Eppendorfcentrifuge 5810R (U.S.)

Nucleic acid condensation instrument: Eppendorfconcentrator 5301 (U.S.)

Ultraviolet spectrophotometer: DU640, balance (Beckman Products)

UV-crosslinked instrument: GS GENE LINKER UV Chamber (BIO-RAD Products)

Water-bath (Memert Products)

Hybridizing box, chip, chip scanner: LuxScan-10K/A (Capitalbio Products)

Horizontal shaker: TDK-2 (the sensible Science and Technology Ltd. in Beijing)

Gel image analyser: GDS-7600 (UPV product)

Superclean bench (Memert Products)

Real-time fluorescence PCR instrument: ABI PRISM7500 (U.S.)

1.3 major experimental reagent

Trizol, glycogen (Invitrogen company)；T4RNA ligase (NEB company)；Control RNA(Capitalbio Company)；5P '-C-U-Cy3-3 ' 5P '-C-U-Cy5-3 ' (Dharmacon company)；Ambion’s miRNA Isolation Kit (Ambion company)；EDPC, first phthalein amine, Australia's phenol are blue (Sigma company)；20 × SSC, 10%SDS (PIERCE company)； 50 × Dhardt ' s (ancient cooking vessel state)；MOPS (Bocherigmer company)；5 × RT Buffer (Promega company of the U.S.), M-MLV Reverse transcriptase: 200u/ μ l (Promega company of the U.S.)；4 × dNTP:10mM each (raw limited public affairs of work biological engineering in Shanghai Department)；RNase inhibitors 4 0u/ μ l (Dalian treasured biological engineering company limited).

The extraction of 1.4 tissue specimen total serum IgE

Trizol one-step method extracts the total serum IgE in tissue specimen.Specifically comprise the following steps that

(1) equipment and the reagent such as mortar, even poly-device, spoon, shears, tweezers, liquid nitrogen are prepared；

(2) mortar pre-cooling: repeatedly add liquid nitrogen in mortar, at least 4-5 time, make the abundant pre-cooling of mortar；

(3) wear gloves, mask, takes out sample with tweezers from liquid nitrogen container rapidly, weighs in analytical balance, once extract Piece of tissue weight between 0.3-0.5g.Piece of tissue is put into and is ground with in the mortar of Liquid nitrogen precooler, and grinding limit, limit adds liquid nitrogen, Whole process does not the most make piece of tissue melt.

(4) after rough lapping, in superclean bench, rapidly the tissue ground is moved into the hook equipped with Trizol reagent with little spoon and fill In device, adding 1ml Trizol by 100mg tissue, homogenate is to the tissue samples granule that is invisible to the naked eye.

(5) transferring in 1.5ml centrifuge tube with dropper by homogenate, often pipe is put into about, more than room temperature placement, preserves to-80 DEG C Until analyzing in refrigerator.

(6) homogenate specimen normal temperature unfreezing, adds chloroform, vortex 30 seconds, room temperature in the ratio of 0.2ml chloroform/1ml Trizol Placing 3min, then 4 DEG C, 12000rpm is centrifuged 15min.

(7) centrifugal rear solution layering, is divided into bottom phenol-chloroform, intermediate layer and upper strata aqueous phase.RNA only exists in aqueous phase, uses Supernatant is transferred to, in the 1.5ml centrifuge tube that another is new, not draw intermediate layer by sample injector.By 0.5ml isopropanol/1ml Trizol Ratio add isopropanol, mixing, room temperature place 4 DEG C of centrifugal 15min of more than 10min, 12000rpm.

(8) supernatant discarded, isopropanol does not reflux too much, can be the ofest short duration centrifugal, with sample injector by remaining isopropanol sucking-off, Add 1ml 75% ethanol, 4 DEG C of centrifugal 5min of vortex, 7500rpm.

(9) discarding 75% ethanol, natural drying 30min in fume hood, traditional vacuum is not dried, and RNA is the most completely dry Thoroughly, in case can not be completely dissolved, with DEPC water dissolution RNA, often pipe is dissolved in 30 μ l, 60-65 DEG C of hydrotropy 5min.

(10) RNA is quantitative, draws the RNA sample of 1 μ l, adds in 49 μ l DEPC water, blow and beat with sample injector mixed up and down Even, dilute 50 times.Blank by the DEPC water gauge note dissolving RNA, draw 50 μ l and add in cuvettes.Use ultraviolet spectrometry light Degree meter DU-640 measures OD value, ratio calculated OD260/OD280 ratio and RNA concentration.

RNA concentration=OD260 × 40 μ g/ml × extension rate.

The separation and Extraction of miRNA in 1.5 total serum IgE

Take 50-100 μ g total serum IgE Ambion ' s miRNAIsolation Kit and separate miRNA, specifically comprise the following steps that

(1) take 50-100 μ g total serum IgE and add EP pipe, be settled to appropriate volume.Add the Lysis/Binding of 5 times of volumes Buffer, mixing.

(2) add ten/the miRNAHomogenate Additive of a volume, vibration mixing, it is placed in and hatches 10 minutes on ice.

(3) add three/100% ethanol of a volume, the most mixed hook.

(4) being added in chimney filter by above-mentioned mixed liquor, 5000rpm is centrifuged 1 minute, collects filtrate (tiny RNA is in filtrate).

(5) in filtrate, add 100% ethanol of 2/3rds volumes, fully mix.

(6) changing chimney filter, filtered by the mixture of step (5), 5000rpm is centrifuged 1 minute, discards filtrate, receives Collector is continuing with.

(7) being placed in collecting pipe by chimney filter, with the miRNAwashing solution 1 filter wash pipe of 700 μ l, 5000rpm is centrifuged 1 minute, discard filtrate.

(8) with the miRNAwashing solution 2 filter wash pipe of 500 μ l, 5000rpm is centrifuged 1 minute, discards filtrate；Again One time is washed with miRNAwashing solution 2；Chimney filter is centrifuged 1 minute together with collecting pipe 10000rpm, removes in chimney filter The liquid of residual.

(9) elution solution is heated to 95 DEG C；Change a new collecting pipe, by the elution solution of 50 μ l 95 DEG C Add filter, close the cover, incubated at room 2 minutes；10000rpm is centrifuged 1 minute, collects filtrate, and tiny RNA is filtrate In.Repeat step (9).

1.6miRNA cDNA microarray

1.6.1miRNA chip

Mammal miRNA chip V3.0 for people 677, rat 292,461 ripe microRNA of mice, due to people, The miRNA three of rat and mice has common sequence, takes the union of three, devises altogether 924 probe (sanger MiRNA data base: miRNABase10.0).These probes with chip point sample instrument Smart-Array TM (Capitalbio Corp, Beijing, China) put and make at a 75 × 25mm, on the microscope slide of chemical modification.Point system sample on chip also wraps Include U6, tRNA of people as internal standard；Outside 30 probes corresponding for bases longs RNA of 8 artificial preparations are as chip Mark (Zip5, Zip13, Zip15, Zip21, Zip23, Zip25, Y2, Y3), Hex as point sample positive control, 50%DMSO As hybridization negative control.

1.6.2miRNA the fluorescent labeling of sample

Specifically comprise the following steps that

(1) fluorescent labeling of miRNA: take 2-5 μ g cancerous tissue miRNA through polyethylene glycol precipitation, with 0.1mgATP, 50mM HEPES、3.5m M DDT、20mM MgCl₂, 10mg/ml BSA, 10%DMSO, 500ng Cy3 labelling 5P '-C-U-Cy3-3 ' (from Dharmacon company) and the T4RNA ligase of 20 units, blow and beat with rifle head, mix gently Even.Tinfoil parcel sample cell, reacts 2 hours at 0 DEG C of labelling.In like manner with Cy5 labelling cancer beside organism miRNA.Two kinds of labellings After miRNA mixing.

(2) purification of miRNA: add DEPC water, polishing to 100 μ l in the sample after above-mentioned fluorescent labeling, add ten 3mmol/L sodium acetate (pH5.2) the 10 μ l of/mono--20 DEG C of pre-coolings of volume, glycogen 10 μ g, 2.5 times of volume dehydrated alcohol, in -20 DEG C stand 1 hour.

(3) rinsing of miRNA precipitation: supernatant discarded, adds 75% ethanol 800 μ l of-20 DEG C of pre-coolings, fully latter 4 DEG C of mixing Lower 12000rpm is centrifuged 5 minutes.It is repeated 2 times.Supernatant discarded, is dried 10min, in atmosphere for chip hybridization after drying up.

1.6.3miRNA chip hybridization

Specifically comprise the following steps that

(1) RNA is dissolved in (15% Methanamide 2.4 μ l in 16 μ l hybridization solutions；0.2%SDS 3.2 μ l；3×SSC 2.4μl；50 × Denhardt ' s 1.6 μ l, DEPC process water 6.4 μ l).

(2) constant-temperature metal bath is heated, and dissolves, vibration, mixing.

(3) take out, place in-20 DEG C of refrigerators 10 minutes, be allowed to lower the temperature.

(4) 95 DEG C of deformation 3min.

(5) cool down the most rapidly, be all added drop-wise on mammal microRNA chip V3.0, add a cover silication coverslip.

(6) the filter paper holding humidity moistened through distilled water after sterilization in hybridizing box, 42 DEG C of hybridized overnight, usual more than 16 hours.

(7) after hybridization terminates, first rinsing 4 minutes in about the 42 DEG C liquid shaking tables containing 0.2%SDS, 2 × SSC, then Containing room temperature in 0.2 × SSC liquid shaking table at room temperature and wash 4 minutes, slide is placed in pipe, and 1600rpm is centrifuged drying in 1 minute After i.e. can be used for scanning.

1.6.4 core body scanner uni data process

Chip Luxscan 10K/A twin-channel laser scanner (Capitalbio company) is scanned.Data are extracted and are used Luxscan 3.0 image analysis software (Capitalbio company), to chip image analysis, is converted into digital signal picture signal.

1.7miRNA chip results real time RT-PCR verifies

1.7.1miRNAreal time RT-PCR primer designs

Special about 56 nucleotide of stem ring primer (reverse transcription primer sequence), its 5 ' 48 nucleotide sequences held are solid Fixed, forming the structure of a stem ring, its 3 ' 8 nucleotide held are just complementary with microRNA.Forward primer (PCR Front primer) it is about 30-31 nucleotide, there is about 16-17 nucleotide complementary with corresponding microRNA at 3 ' ends, and remain Yu the Tm value of 14 nucleotide higher than 65 degrees Celsius.General reverse primer (primer after PCR) is about 23nt, and wherein 18 The loop-stem structure of individual nucleotide correspondence specific reverse primer, and the Tm value of 5 ' hold 5 nucleotide is higher than 65 degrees Celsius.

1.7.2miRNAreal time RT-PCR

1.7.2.1cDNA reverse transcription synthesis

Tissue specimen total serum IgE reverse transcription synthesis cDNA, reaction system is as follows:

Component	Volume (unit: μ l)
		Total serum IgE template	1 μ g (calculates volume according to concentration)
Stem-loop RT primer(500nM)	1
		5×RT Buffer	2
100mM DTT	1
		dNTPs(10mM each)	0.5
RNase inhibitor (40U/ μ l)	0.1
		M-MLV(200U/μl)	1
Add DEPC water	To 10 μ l

Reaction condition: 16 DEG C, 30min；42 DEG C, 60min；85 DEG C, 5min；4 DEG C, hold.

1.7.2.1miRNAreal time RT-PCR reacts

MiRNA real time RT-PCR reaction system is as follows:

Component	Volume (unit: μ l)
		SYBR^RPremix Ex Taq^TM(2×)	12.5
Forward primer 10 μMs	0.5
		Reversely universal primer μM	0.5
ROX Reference DyeⅡ(50×)	0.5
		DNA profiling (dilutes 10 times)	2
DEPC processes water	To 25

Reaction condition: 95 DEG C of denaturations 10min；95℃5s、60℃34s×40.

1.8 statistical analysis

The result of gene chip screening uses Cluster 3.0 and Significance Analysis ofMicroarrys (SAM, version 2.1) it is analyzed.Data with (± represent, compare between group employing inspection, use software be analyzed process, have system for difference Meaning learned by meter.Real time RT-PCR data represent with (x ± s), compare employing t inspection, use SPSS 17.0 soft between group Part is analyzed processing, and P ＜ 0.05 is that difference is statistically significant.

2 results

2.1miRNA gene chip the selection result

Utilize miRNA chip that 924 kinds of miRNA expressions in the cancer beside organism of 8 pairs of renal carcinoma tissues and pairing are analyzed, Filter out miRNA, wherein hsa-miR-424-5p, hsa-miR-193b, hsa-miR-224-5p that 23 species diversity are expressed altogether Up-regulated, hsa-miR-145, hsa-miR-381, hsa-miR-132, hsa-miR-206, hsa-miR-199b-5p, hsa-miR-384、hsa-miR-335、hsa-miR-497、hsa-miR-99a、hsa-miR-10b-5p、hsa-miR-125b、 has-let-7b、hsa-miR-10a、hsa-miR-126、hsa-miR-30a、hsa-miR-143、hsa-miR-125a-5p、 Hsa-miR-19b, hsa-miR-26a, rno-miR-324-3p down-regulated expression.

The real time RT-PCR checking of 2.2miRNA gene chip the selection result

With miRNA real time RT-PCR, the result of chip examination is verified, filter out what 10 species diversity were expressed altogether MiRNA, wherein, hsa-miR-424-5p, hsa-miR-224-5p and hsa-miR-193b up-regulated, hsa-miR-384, Hsa-miR-206, hsa-miR-381, hsa-miR-132, hsa-miR-497, hsa-miR-99a, hsa-miR-10b-5p express Lower.5 kind miRNAs, hsa-miR-10b-5p obvious to wherein different expression, hsa-miR-384, hsa-miR-424-5p, Hsa-miR-206 and hsa-miR-224-5p carries out further serology expression analysis.

Embodiment 2: the serological analysis of diversity miRNA in renal carcinoma tissue

1 object and method

1.1 Specimen origin

Obtaining after patient's informed consent, collecting the hospitals of traditional Chinese and western medicine of Jiangsu Province in Mays, 2013 to example August 165 in 2014 Through the clear and definite patients with renal cell carcinoma of pathological diagnosis and 120 example Healthy People limosis vein blood in early morning 6ml as comparison.All patients with renal cell carcinoma are equal For first patient diagnosed, do not carry out before taking blood performing the operation, radiotherapy and chemotherapeutic treatment.120 example normal healthy controls groups are pernicious for not suffering from Tumor and other diseases, the simultaneously healthy population of age-matched.

1.2 serum sample collection and process

Extraction limosis vein blood 6ml in early morning is placed in without in the pipe of anticoagulant, stands 30 minutes, in 4 DEG C of 1300g (or 4000rpm) Centrifugal 15 minutes, take the every 300 μ l subpackages of upper serum and be placed in-80 DEG C of refrigerator storage to RNase-free EP pipe.

1.3 key instrument equipment

Eppendorfcentrifuge (U.S.)；Horizontal laminar flow clean bench (memert company)；Ultraviolet spectrophotometer nano (Thermo science and technology)；Water-bath (memert company)；Real-time PCR instrument CFX96 (Germany BIO-RAD)；Vortex Whirlpool concussion instrument (U.S. SI)；Ultra cold storage freezer (Thermo science and technology)；Milli Q demineralizer (Synthesis company).

1.4 major experimental reagent

Blood total serum IgE rapid extraction test kit (Beijing hundred Imtech)；Lysate RLS；Protein liquid removal RE；Rinsing liquid RW；RNase-free H₂O；70% ethanol；RNase-free adsorptivity RA；MiRcute miRNA cDNA the first chain synthesizes Test kit (TIANGEN)；E.coli Poly(A)Polymerase(5U/ml)；10×Poly(A)Polymerase Buffer；5 ×rATP Solution；10×RT Prime；10×RT Buffer；Super Pure dNTP Mixture；Rnasin；Quant RTase； RNase–Free ddH₂O；MiRcute miRNA fluorescence quantitative detection kit (TIANGEN)；2×miRNApremix (SYBRROX)；Reverse primer；50×ROXReference Dye；Chloroform (Sigma company).

1.5 design of primers

1.6 experimental technique

1.6.1 serum sample Total RNAs extraction

(1) every 250 μ l serum add 750 μ l lysate RLS, with sample loading gun piping and druming sample several times, and lysate RLS and liquid The final volume of sample is than always 3:1.

(2) sample acutely shaking mixing, incubated at room temperature 5 minutes is so that ribosome decomposes completely.

Under the conditions of (3) 4 DEG C, 12000rpm is centrifuged 10 minutes, carefully takes in the centrifuge tube that supernatant proceeds to new RNase free.

(4) every milliliter of RLS adds 0.2ml chloroform, covers tightly sample lid, and acutely concussion 15 seconds ambient temperatare put 3 minutes.

(5) being centrifuged 10 minutes in 4 DEG C of 12000rpm, sample can be divided into three layers: lower floor's organic facies, intermediate layer and upper strata are colourless Aqueous phase, RNA is present in aqueous phase.The capacity of aqueous layer is about the 70% of added RLS volume, and aqueous phase is transferred to newly Guan Zhong, carries out next step operation.

(6) 1 times of volume 70% ethanol is added, reverse mixing (now it is possible that precipitate).The solution obtained and may sinking Form sediment and proceed to (adsorption column is enclosed within collecting pipe) in RA post together.

(7) 10000rpm is centrifuged 45 seconds, discards waste liquid, and adsorption column is recovered collecting pipe again.

(8) adding 500 μ l protein liquid removal RE, 12000rpm is centrifuged 45 seconds, discards waste liquid.

(9) adding 700 μ l rinsing liquid RW, 12000rpm is centrifuged 60 seconds, discards waste liquid.

(10) adding 700 μ l rinsing liquid RW, 12000rpm is centrifuged 60 seconds, discards waste liquid.

(11) putting back in sky collecting pipe by adsorption column RA, 12000rpm is centrifuged 2 minutes, removes rinsing liquid as far as possible, in order to avoid drift Residual ethanol suppression downstream reaction in washing liquid.

(12) take out adsorption column RA, put in a RNase free centrifuge tube, add 30 μ l things in the middle part of adsorbed film The first RNase free water of heating in 65 DEG C of water-baths, room temperature placement 2 minutes, 12000rpm is centrifuged 1 minute, will obtain Solution rejoin in centrifugal adsorbing column, centrifugal 1 minute.

1.6.2cDNA transcribe

After blood serum sample Total RNAs extraction, use and add poly A tract Poly (A) at miRNA 3 ' end, re-use oligo (dT) the general reverse transcriptase primer of-universal tag carries out reverse transcription reaction, ultimately generates cDNA the first chain corresponding for miRNA.

1.6.2.1miRNA 3 ' ends carry out Poly (A) process

(1) add following reagent in the reaction tube of pre-cooling RNase free on ice and (be eventually adding E.coli to cumulative volume 20 μ l Poly(A)Polymerase)。

Component	Volume (μ l)	Final concentration
			Total serum IgE		Up to 2 μ g
E.coli Poly(A)Polymerase	0.4	2U
			10×Poly(A)Polymerase Buffer	2	1×
10×rATP solution	4	1×
			RNase free ddH₂O	-	-
Cumulative volume	20	-

(2) pipettor mixes the reactant liquor of above-mentioned preparation gently, of short duration centrifugal after react 60 minutes at 37 DEG C, continue experiment.

1.6.2.2Poly the miRNA that (A) modifies carries out reverse transcription reaction

The preparation of reactant liquor is carried out according to following table component

Component	Volume (μ l)
		Poly (A) reactant liquor	2
10×stem-loop RT Prime	2
		10×RT Buffer	2
Super Pure dNTP Mixture	1
		Rnasin	1
Quant RTase	0.5
		RNase-Free ddH₂O	11.5
Cumulative volume	20

1.6.3real time RT-PCR

(1) room temperature melts 2 × miRNApremix (SYBR) and Reverse primer.

(2) 2 × miRNApremix (SYBR) is turned upside down mix gently, it is to avoid bubble, use after light gentle centrifugation.

(3) reagent is placed on ice, and prepares reaction volume according to following table.

Component	50 μ l systems	Final concentration
			2×miRNA premix(SYBR)	25	1×
Forward primer	-	200nM
			Reverse primer	1	200nM
MiRNA the first chain cDNA	-	-
			ddH₂O	To 50 μ l	-

PCR response procedures is arranged according to following table

Circulation	Temperature (DEG C)	Time	Content
				1×	94	2min	Starting template degeneration
40-45×	94	20s	Template denaturation in PCR cycle
					60	34s	Annealing, extension

1.6.4PCR data process

PCR amplification CT value represents, CT value is meant that in PCR reactant liquor that fluorescence signal reaches set threshold Period during value.The relative expression of sample genes of interest leads (RQ) and uses △ △ CT method to calculate, RQ=2^-△△CT(CT The real-time fluorescence intensity of expression reaction is noticeably greater than period during background value, △ CT sample=CT sample CT U6 Sample, △ CT control=CT control CT U6control, △ △ CT=△ CT sample-△ CT control).

1.7 statistical analysis

Using SPSS 17.0 statistical software to carry out data process, measurement data represents with (x ± s), compares employing t inspection between group, Serum miRNA relative expression quantity uses Mann Whiney inspection and Kruskal Wallis with the relation of renal carcinoma clinical pathologic characteristic Inspection.P ＜ 0.05 is that difference is statistically significant.

2 results

The real time RT-PCR detection of 2.1 serum targets miRNA

Target miRNA expression in 165 example patients with renal cell carcinoma and 120 example normal healthy controls group serum has been carried out quantitatively by this research Analyzing, employing U6 is internal standard, and result shows that miRNA is stable in serum and expresses, reliable and stable as internal reference with U6.

Target miRNA expression in 2.2 patients with renal cell carcinoma and matched group serum

Matched group and renal carcinoma group hsa-miR-384, hsa-miR-424-5p, hsa-miR-206, hsa-miR-224-5p and Hsa-miR-10b-5p relative expression quantity compares, difference the most statistically significant (P ＜ 0.05).

Data see table.

Group	hsa-miR-224-5p	hsa-miR-384	hsa-miR-424-5p	hsa-miR-206	hsa-miR-10b-5p
						Matched group	1.04±0.22	1.21±0.29	1.09±0.26	0.90±0.12	0.94±0.17
Renal carcinoma group	2.86±0.25	0.58±0.32	2.88±0.23	0.47±0.14	0.42±0.21
						T value	2.552	2.694	2.548	2.371	2.395
P value	0.011	0.012	0.015	0.010	0.011

The present invention utilizes miRNA chip to be analyzed miRNA express spectra in the cancer beside organism of 8 pairs of renal carcinoma tissues and pairing, Filtering out the miRNA that 23 species diversity are expressed altogether, chip results is verified by real-time fluorescence quantitative RT-PCR, altogether sieve Select the miRNA that 10 species diversity are expressed, wherein hsa-miR-424-5p, hsa-miR-224-5p and hsa-miR-193b table Reach rise, hsa-miR-384, hsa-miR-206, hsa-miR-381, hsa-miR-132, hsa-miR-497, hsa-miR-99a, Hsa-miR-10b-5p down-regulated expression.Tumor is the result that a series of molecular biology behavior change is accumulative, relates to thin The various aspects such as born of the same parents' cycle, apoptosis, proliferation and differentiation, the change that a series of miRNA therefore should be had to express participates in tumor Generation, the result verification of gene chip this it is assumed that the expression of multiple miRNA there occurs change.

5 kinds of miRNA of differential expression substantially (differential expression amount is more than 2 fold, and in RT-PCR, CT value is less than 30), Hsa-miR-10b-5p, hsa-miR-384, hsa-miR-424-5p, hsa-miR-206 and hsa-miR-224-5p are carried out further Serology expression analysis.Result shows that miRNA is stable in serum and expresses, and the expression of serum miRNA and tissue have very Good concordance, hsa-miR-10b-5p, hsa-miR-384 and hsa-miR-206 down-regulated expression, hsa-miR-424-5p and Hsa-miR-224-5p up-regulated.Result shows, these 5 kinds of miRNA can be as the biomarker of Diagnosis of Renal Cell Carcinoma.

Embodiment 3: Receiver operating curve (ROC) analyzes

Build ROC curve and compare 5 serum miRNA differentiation renal carcinoma patients and the diagnosis capability of normal healthy controls.5 miRNA Under ROC curve, area (AUC) is respectively as follows: hsa-miR-10b-5p, 0.796 (95% confidence interval: 0.760-0.920)； Hsa-miR-384,0.789 (95% confidence interval: 0.736-0.902)；Hsa-miR-206,0.774 (95% confidence interval: 0.734-0.894)；Hsa-miR-424-5p, 0.793 (95% confidence interval: 0.765-0.920)；Hsa-miR-224-5p, 0.732 (95% confidence interval: 0.644-0.832).Under optimal cut off value, sensitivity and the specificity of miRNA are as follows: Hsa-miR-10b-5p, respectively 83.3% and 82.7%；Hsa-miR-384, respectively 64.8% and 94.2%；Hsa-miR-206, It is respectively 90.7% and 61.5%；Hsa-miR-424-5p, respectively 70.4% and 82.5%；Hsa-miR-224-5p, is respectively 67.3% and 74.1%.The AUC that these 5 miRNA join together can reach 0.992, and sensitivity and specificity are respectively 92.3% With 91.9%, hence it is evident that be better than single miRNA.This result shows, hsa-miR-10b-5p, hsa-miR-384, hsa-miR-206, Hsa-miR-424-5p and hsa-miR-224-5p joins together that renal carcinoma detection is had the highest sensitivity and specificity.

Embodiment 4: people's Diagnosis of Renal Cell Carcinoma test kit

Above-described embodiment shows, hsa-miR-10b-5p, hsa-miR-384, hsa-miR-206, hsa-miR-424-5p and Hsa-miR-224-5p joins together that renal carcinoma detection had the highest sensitivity and specificity, therefore, and can be based on Hsa-miR-10b-5p, hsa-miR-384, hsa-miR-206, hsa-miR-424-5p and hsa-miR-224-5p make for people The test kit of Diagnosis of Renal Cell Carcinoma.This test kit includes hsa-miR-10b-5p primer, probe；Hsa-miR-384 primer, probe； Hsa-miR-206 primer, probe；Hsa-miR-424-5p primer, probe；Hsa-miR-224-5p primer, probe.Primer has Body includes before reverse transcription primer, quantitative PCR primer after primer and quantitative PCR.Certainly, this test kit also should include inverse Transcriptase, buffer, dNTPs, MgCl₂, DEPC water, Taq enzyme and standard substance and/or reference substance.Following table be primer and A kind of design of probe.

The design of primer and probe is this area routine techniques means, can be designed to other sequences.

The effect of above-described embodiment indicates that the essentiality content of the present invention, but does not limit protection scope of the present invention with this. It will be understood by those within the art that, technical scheme can be modified or equivalent, and not take off Essence and protection domain from technical solution of the present invention.

Claims

1. one group of microRNA biomarker for people's Diagnosis of Renal Cell Carcinoma, it is characterised in that including: hsa-miR-10b-5p, Hsa-miR-384, hsa-miR-206, hsa-miR-424-5p and hsa-miR-224-5p；The nucleoside of described hsa-miR-10b-5p Acid sequence is as shown in SEQ ID NO.1；The nucleotide sequence of described hsa-miR-384 is as shown in SEQ ID NO.2；Described The nucleotide sequence of hsa-miR-206 is as shown in SEQ ID NO.3；The nucleotide sequence of described hsa-miR-424-5p is such as Shown in SEQ ID NO.4；The nucleotide sequence of described hsa-miR-224-5p is as shown in SEQ ID NO.5.

MicroRNA biomarker for people's Diagnosis of Renal Cell Carcinoma the most according to claim 1, it is characterised in that: described MicroRNA biomarker is human serum microRNA biomarker.

3. lineup's Diagnosis of Renal Cell Carcinoma microRNA primer, the combination of probe, it is characterised in that: include hsa-miR-10b-5p Primer, probe, hsa-miR-384 primer, probe, hsa-miR-206 primer, probe, hsa-miR-424-5p primer, spy Pin, hsa-miR-224-5p primer, probe；Described primer includes before reverse transcription primer, quantitative PCR after primer and quantitative PCR Primer；The reverse transcription primer sequence of hsa-miR-10b-5p is as shown in SEQ ID NO.6, and before quantitative PCR, primer sequence is such as Shown in SEQ ID NO.7, after quantitative PCR, primer sequence is as shown in SEQ ID NO.16；The reverse transcription primer of hsa-miR-384 Sequence is as shown in SEQ ID NO.8, and before quantitative PCR, primer sequence is as shown in SEQ ID NO.9, primer sequence after quantitative PCR Row are as shown in SEQ ID NO.16；The reverse transcription primer sequence of hsa-miR-206 as shown in SEQ ID NO.10, quantitative PCR Front primer sequence is as shown in SEQ ID NO.11, and after quantitative PCR, primer sequence is as shown in SEQ ID NO.16； The reverse transcription primer sequence of hsa-miR-424-5p is as shown in SEQ ID NO.12, and before quantitative PCR, primer sequence is such as Shown in SEQ ID NO.13, after quantitative PCR, primer sequence is as shown in SEQ ID NO.16；The reverse transcription of hsa-miR-224-5p Primer sequence is as shown in SEQ ID NO.14, and before quantitative PCR, primer sequence is as shown in SEQ ID NO.15, after quantitative PCR Primer sequence is as shown in SEQ ID NO.16；The nucleotide sequence of each microRNA probe is as shown in SEQ ID NO.17.

4. the tumor diagnosis kit of people's renal carcinoma, it is characterised in that: include that microRNA as claimed in claim 3 draws Thing, the combination of probe.

The tumor diagnosis kit of people's renal carcinoma the most according to claim 4, it is characterised in that: also include reverse transcriptase, delay Rush liquid, dNTPs, MgCl₂, DEPC water, Taq enzyme and standard substance and/or reference substance.